{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T14:36:26Z","timestamp":1787841386688,"version":"build-2784847793"},"reference-count":16,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":424,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Radioactive iodine (RAI) treatment is an established therapeutic tool for \u2018differentiated thyroid cancers\u2019. The therapeutic effectiveness is linked to the preservation of the iodine-concentrating ability of the neoplastic tissue, a unique, inherent quality of a normal thyroid gland. Iodine concentration is a function involving the expression of transport proteins and organification. Thyroid differentiation score (TDS) is an integrated quantity, first introduced by The Cancer Genome Atlas (TCGA), conveying the relative expression of proteins involved in histogenesis, morphologic and functional differentiation of thyroid tissue. The concept is well described for the expression of metabolic suppression of thyroid cancers associated with RAI-refractoriness. We evaluated the mRNA expressions of thyroid metabolomics-specific genes, comparing normal thyroid to neoplastic tissue in a cohort where patient-specific paired data were available. Fifty-nine papillary thyroid cancer samples from the TCGA project with matched tumor-normal tissue samples were analyzed. Of the 59 samples, 29 contained a BRAFV600E mutation, seven a RAS mutation, 10 a mutation other than BRAF or RAS, and 14 either no mutation or an unknown mutation. Our analysis demonstrated that there was a significant downregulation of the RAI theranostic transcriptome, much more significant in BRAF-initiated cancers vs RAS-initiated ones. There was also notable heterogeneity in respective mutational categories where individual assessment of the thyroid differentiation profile (TDP) would potentially be clinically relevant for RAI treatment planning. Determination of TDP and development of a theranostic TDS may have an impact on clinical decision making as to the extent of thyroidectomy and postoperative RAI therapy.<\/jats:p>","DOI":"10.1530\/eo-24-0072","type":"journal-article","created":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T09:47:30Z","timestamp":1737712050000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":4,"title":["Thyroid differentiation profile for differentiated thyroid cancer"],"prefix":"10.1530","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3714-4676","authenticated-orcid":true,"given":"Anthony J","family":"McGoron","sequence":"first","affiliation":[{"name":"Florida International University, College of Engineering and Computing 1 , , ,","place":["Miami, Florida, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M","family":"Garcia","sequence":"additional","affiliation":[{"name":"Florida International University, College of Arts Science and Education 2 , , ,","place":["Miami, Florida, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burul\u00e7a","family":"Uluvar","sequence":"additional","affiliation":[{"name":"3Computational Medicine, Berlin Institute of Health at Charit\u00e9 - Universit\u00e4tsmedizin Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seza A","family":"Gulec","sequence":"additional","affiliation":[{"name":"HCA Florida Aventura Hospital 4 , , ,","place":["Aventura, Florida, USA"]},{"name":"Miami Cancer Research Center 5 , , ,","place":["Miami, Florida, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2025,1,24]]},"reference":[{"key":"2026070713300709200_bib1","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1210\/clinem\/dgab851","article-title":"Characterization of subtypes of BRAF-mutant papillary thyroid cancer defined by their thyroid differentiation score","volume":"107","author":"Boucai","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713300709200_bib2","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1001\/jama.2023.26348","article-title":"Thyroid cancer: a review","volume":"331","author":"Boucai","year":"2024","journal-title":"JAMA"},{"key":"2026070713300709200_bib3","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell"},{"key":"2026070713300709200_bib4","doi-asserted-by":"crossref","first-page":"4700","DOI":"10.1172\/JCI46382","article-title":"Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation","volume":"121","author":"Chakravarty","year":"2011","journal-title":"J Clin Invest"},{"key":"2026070713300709200_bib5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1210\/jc.2018-01478","article-title":"Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers","volume":"104","author":"Dunn","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713300709200_bib6","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4274\/mirt.galenos.2020.83703","article-title":"A review of the history of radioactive iodine theranostics: the origin of nuclear ontology","volume":"29","author":"Ehrhardt","year":"2020","journal-title":"Mol Imaging Radionucl Ther"},{"key":"2026070713300709200_bib7","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1089\/thy.2020.0826","article-title":"A joint statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on current diagnostic and theranostic approaches in the management of thyroid cancer","volume":"31","author":"Gulec","year":"2021","journal-title":"Thyroid"},{"key":"2026070713300709200_bib8","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.3390\/jcm13133645","article-title":"Molecular perspectives in radioactive iodine theranostics: current redifferentiation protocols for mis-differentiated thyroid cancer","volume":"13","author":"Gulec","year":"2024","journal-title":"J Clin Med"},{"key":"2026070713300709200_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s42003-019-0503-6","article-title":"Congenital goitrous hypothyroidism is caused by dysfunction of the iodide transporter SLC26A7","volume":"2","author":"Ishii","year":"2019","journal-title":"Commun Biol"},{"key":"2026070713300709200_bib10","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1186\/1471-2105-12-323","article-title":"RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome","volume":"12","author":"Li","year":"2011","journal-title":"BMC Bioinformatics"},{"key":"2026070713300709200_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.2967\/jnumed.119.227652","article-title":"The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer","volume":"61","author":"Liu","year":"2020","journal-title":"J Nucl Med"},{"key":"2026070713300709200_bib12","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1210\/clinem\/dgad697","article-title":"Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid cancer","volume":"109","author":"Mu","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713300709200_bib13","doi-asserted-by":"crossref","first-page":"E829","DOI":"10.1210\/jc.2012-3933","article-title":"Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases","volume":"98","author":"Sabra","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070713300709200_bib14","first-page":"751","article-title":"The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma","volume":"64","author":"Scheffel","year":"2020","journal-title":"Arch Endocrinol Metab"},{"key":"2026070713300709200_bib15","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1001\/jama.1946.02870490016004","article-title":"Radioactive iodine therapy","volume":"132","author":"Seidlin","year":"1946","journal-title":"J Am Med Assoc"},{"key":"2026070713300709200_bib16","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15151-4","article-title":"The iodide transporter Slc26a7 impacts thyroid function more strongly than Slc26a4 in mice","volume":"12","author":"Yamaguchi","year":"2022","journal-title":"Sci Rep"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/5\/1\/EO-24-0072.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/5\/1\/EO-24-0072.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-24-0072\/194466\/eo-24-0072.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-24-0072\/194466\/eo-24-0072.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:51:33Z","timestamp":1783446693000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/5\/1\/e240072\/34822\/Thyroid-differentiation-profile-for-differentiated"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":16,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-24-0072","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]},"article-number":"e240072"}}